# A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.

> **NCT07689812** · NA · NOT_YET_RECRUITING · sponsor: **Natera, Inc.** · enrollment: 920 (estimated)

## Conditions studied

- NSCLC (Advanced Non-small Cell Lung Cancer)
- NSCLC (Non-small Cell Lung Cancer)
- NSCLC (Non-small Cell Lung Carcinoma)
- NSCLC
- Melanoma (Skin Cancer)
- Melanoma (Skin) Stage IV
- CRC
- MSI High Colorectal Cancer
- DMMR Colorectal Cancer
- RCC, Renal Cell Cancer
- RCC
- Solid Tumors
- Metastatic Solid Tumors
- Advanced Solid Tumors
- Advanced Solid Tumors Cancer

## Interventions

- **DEVICE:** Signatera Genome ultra-sensitive ctDNA blood test

## Key facts

- **NCT ID:** NCT07689812
- **Lead sponsor:** Natera, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-12
- **Primary completion:** 2033-12
- **Final completion:** 2034-03
- **Target enrollment:** 920 (ESTIMATED)
- **Last updated:** 2026-08-04


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07689812

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07689812, "A Multicenter Randomized Open-Label Trial Evaluating ctDNA-Guided Interruption Versus Standard of Care Immune-Checkpoint Inhibitor (ICI) Therapy In Patients With Advanced / Metastatic Solid Tumors.". Retrieved via MORVS 2026-10-20 from https://api.morvs.ai/clinical/NCT07689812. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*